StreetInsider.com News Articles

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Mon, 24 Aug 2026 20:30:00 -0400

SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Phase I ATTRACT study of our proprietary ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B cell-related autoimmune diseases, has received approval from the Human Research Ethics Committee (HREC) in Australia, and completed the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA).

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Mon, 24 Aug 2026 20:30:00 -0400

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Mon, 24 Aug 2026 20:30:00 -0400

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Mon, 24 Aug 2026 20:30:00 -0400

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

Sun, 23 Aug 2026 21:00:00 -0400

SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today provided an overview of its interim results for the period ended June 30, 2026, which were announced on August 21, 2026, together with recent business highlights and strategic progress.

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

Sun, 23 Aug 2026 21:00:00 -0400

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

Sun, 23 Aug 2026 21:00:00 -0400

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

Sun, 23 Aug 2026 21:00:00 -0400

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

Tue, 18 Aug 2026 21:00:00 -0400

SHANGHAI and HONG KONG, Aug. 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Company has been invited to participate in the Evercore 2nd China Biotech Summit, where it presented multiple key R&D highlights during a fireside chat. At the event, the Company presented updated clinical data for ATG–022 (CLDN18.2 antibody–drug conjugate [ADC]). Regarding T–cell engager (TCE) technologies,

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

Tue, 18 Aug 2026 21:00:00 -0400

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

Tue, 18 Aug 2026 21:00:00 -0400

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

Tue, 18 Aug 2026 21:00:00 -0400

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

Mon, 20 Jul 2026 03:00:00 -0400

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that two clinical abstracts featuring the latest results from the Phase II study of Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 and the Phase Ib/II study of oral CD73 small-molecule inhibitor ATG-037 have been accepted for poster presentation at the 2026 European Society

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

Mon, 20 Jul 2026 03:00:00 -0400

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that two clinical abstracts featuring the latest results from the Phase II study of Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 and the Phase Ib/II study of oral CD73 small-molecule inhibitor ATG-037 have been accepted for poster presentation at the 2026 European Society

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

Mon, 20 Jul 2026 03:00:00 -0400

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that two clinical abstracts featuring the latest results from the Phase II study of Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 and the Phase Ib/II study of oral CD73 small-molecule inhibitor ATG-037 have been accepted for poster presentation at the 2026 European Society

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

Mon, 20 Jul 2026 03:00:00 -0400

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that two clinical abstracts featuring the latest results from the Phase II study of Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 and the Phase Ib/II study of oral CD73 small-molecule inhibitor ATG-037 have been accepted for poster presentation at the 2026 European Society

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

Mon, 13 Jul 2026 00:00:00 -0400

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the company has received a USD 60 million upfront payment from UCB. This payment is made pursuant to the worldwide exclusive license agreement for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, entered into between the parties in March 2026.

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

Mon, 13 Jul 2026 00:00:00 -0400

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the company has received a USD 60 million upfront payment from UCB. This payment is made pursuant to the worldwide exclusive license agreement for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, entered into between the parties in March 2026.

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

Mon, 13 Jul 2026 00:00:00 -0400

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the company has received a USD 60 million upfront payment from UCB. This payment is made pursuant to the worldwide exclusive license agreement for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, entered into between the parties in March 2026.

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

Mon, 13 Jul 2026 00:00:00 -0400

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the company has received a USD 60 million upfront payment from UCB. This payment is made pursuant to the worldwide exclusive license agreement for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, entered into between the parties in March 2026.

Antengene licenses ATG-106 to K2 Therapeutics for up to $980M

Sun, 21 Jun 2026 20:30:20 -0400

Antengene Corporation Limited (SEHK: 6996.HK) announced it has entered into an exclusive license agreement with K2 Therapeutics, granting the company global rights, excluding Greater China, to develop and commercialize ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager (TCE) being developed for solid tumors including ovarian and renal cancers.

Under the license agreement, Antengene will receive upfront and near-term considerations of approximately $20 million, consisting of cash and a minority equity stake in a newly established asset company and subsidiary of K2 Therapeutics, subject to certain conditions. Antengene is also eligible to receive up to $960.5 million in developmental, regulatory,

Antengene licenses ATG-106 to K2 Therapeutics for up to $980M

Sun, 21 Jun 2026 20:30:20 -0400

Antengene Corporation Limited (SEHK: 6996.HK) announced it has entered into an exclusive license agreement with K2 Therapeutics, granting the company global rights, excluding Greater China, to develop and commercialize ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager (TCE) being developed for solid tumors including ovarian and renal cancers.

Under the license agreement, Antengene will receive upfront and near-term considerations of approximately $20 million, consisting of cash and a minority equity stake in a newly established asset company and subsidiary of K2 Therapeutics, subject to certain conditions. Antengene is also eligible to receive up to $960.5 million in developmental, regulatory,

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

Sun, 21 Jun 2026 20:30:00 -0400

ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China
Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones
K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China
The deal underscores AnTenGager^® platform's differentiated capabilities in

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

Sun, 21 Jun 2026 20:30:00 -0400

ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China
Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones
K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China
The deal underscores AnTenGager^® platform's differentiated capabilities in

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

Sun, 21 Jun 2026 20:30:00 -0400

ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China
Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones
K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China
The deal underscores AnTenGager^® platform's differentiated capabilities in